Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome. (IBS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Michigan Gastroenterology Institute.
Recruitment status was  Not yet recruiting
Information provided by:
Michigan Gastroenterology Institute Identifier:
First received: February 15, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted

February 15, 2011
February 15, 2011
April 2011
December 2011   (final data collection date for primary outcome measure)
IBS Quality of Life Inventory(IBS QOLF) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Significant improvement in IBS QOLF score in the treatment group
Same as current
No Changes Posted
Behavioral Symptom Inventory [ Time Frame: 6 months ] [ Designated as safety issue: No ]
improvement in emotional function
Same as current
Not Provided
Not Provided
Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.
Examining Patient Attributes To Determine Optimal Treatment Outcome in Irritable Bowel Syndrome.

The purpose of this study is to determine if any specific patient characteristics lead to improved outcome of IBS treatment, when conventional treatment as well as Cognitive Behavioral Therapy is used in combination.

Although research has demonstrated the efficacy of various psychological and pharmacological treatments for irritable bowel syndrome (IBS)1, health professionals have limited information about how to determine which specific treatment regimens lead to optimal outcomes for specific IBS populations 2,3. A prevalent syndrome, with high healthcare costs, IBS is a debilitating chronic functional bowel disorder with increasingly interconnected psychosocial and gastrointestinal afflictions4. In general, IBS sufferers have not been found to respond consistently to a single medication or class of medications5. In the wake of the failures of medical therapies, many psychological interventions, adjunct to standard IBS treatments, have been examined1,6 such as Blanchard and Scharff's 2002 review of 12 random controlled trials that found strong evidence for the utility of hypnotherapy, cognitive behavioral therapy (CBT), and brief psychodynamic psychotherapy in helping to alleviate IBS symptoms7. Similarly, in a more recent study involving a meta-analysis of seventeen studies, with randomized trials comparing classes of psychological interventions, found that these psychological treatments also play a role in improving quality of life of IBS suffers1. Among these psychological interventions, cognitive behavioral therapy (CBT), a prescriptive therapy that specifically targets faulty thinking patterns, has been found to be quite effective in many empirical investigations. Recent evaluations of CBT interventions have found the therapy to have a direct effect on global improvements of IBS symptoms and quality of life8. Despite its demonstrated effectiveness, however, CBT does not work for all patients3,6,8. The successes of medical therapy alone compared to a treatment regimen combining psychological and pharmaceutical interventions have been greeted with mixed results— leading to the unnecessary waste of health resources in the course of treatment3,6. To decrease medical costs, as well to foster optimal treatment for IBS patients, there is a need for a better method of identifying which patients will most benefit from specific treatment options s (i.e. conventional medical treatment versus standard treatment and CBT)2,3.

Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Irritable Bowel Syndrome
Behavioral: Cognitive Behavior Therapy(CBT)
Cognitive Behavior Therapy(CBT) for 6 weeks.
Other Name: Cognitive Behavior Therapy(CBT)
  • No Intervention: Control group
    Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
  • Experimental: Treatment
    Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
    Intervention: Behavioral: Cognitive Behavior Therapy(CBT)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not yet recruiting
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All newly diagnosed IBS patients using Rome III criteria above the age of 18.

Exclusion Criteria:

  • Patients with non-functional GI disorders, severe psychiatric disorders, including psychotic disorders, actively suicidal or alcoholism/other drug dependencies.
  • Pregnant women and minors(under age 18) will also be excluded.
  • Prisoners will also be excluded.
18 Years and older
Contact: Iftiker Ahmad, M.D. 517.332.1200 ext 221
Contact: Priscilla Wade, Ph.D 517.336.7366
United States
Iftiker Ahmad, M.D., Michigan Gastroenterology Institute
Michigan Gastroenterology Institute
Not Provided
Principal Investigator: Iftiker Ahmad, M.D. Michigan Gastroenterology Institute
Michigan Gastroenterology Institute
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP